Retatrutide

Retatrutide as an active ingredient in obesity research

Retatrutide is being investigated in clinical trials primarily in the context of medical weight management. The active ingredient targets hormonal regulatory systems that can influence hunger, satiety, food intake, blood sugar regulation, energy balance, and metabolic processes.

• Obesity research: Retatrutide is being investigated as a potential active ingredient for weight reduction and long-term weight management.
• Metabolic medicine: The active ingredient is also being studied in connection with metabolic risk factors, for example in weight-related comorbidities.
• Triple agonism: Retatrutide acts on GLP-1, GIP, and glucagon receptors and therefore differs from pure GLP-1 active ingredients.
• Clinical development: Retatrutide is in clinical development and is currently not a regularly available treatment option in Germany.
• Medical classification: Whether medication-based treatment is suitable depends on the diagnosis, BMI, comorbidities, risks, current medication, and individual medical suitability.

This distinction is important because search queries about retatrutide are often shaped by high expectations. However, a promising active ingredient in clinical trials is not automatically an approved, available, or individually suitable medication.

Retatrutide in active ingredient development

Retatrutide is currently best known as an experimental active ingredient from clinical trials. At this time, no regularly approved medication containing retatrutide has been documented for Germany or the European Union. Patients who would like an initial overview of available medication-based options can find further information on our page about weight loss medications for medical weight management.

Active ingredient	Active ingredient class	Use in clinical trials	Current classification
Retatrutide	GLP-1/GIP/glucagon receptor agonist	Injection, usually once weekly in clinical trials	Experimental active ingredient in clinical development; no regular approval or availability documented for Germany/EU; not currently offered by The Body Clinic

How does retatrutide work in the body?

Retatrutide is described as a triple agonist because the active ingredient targets three receptor systems: GLP-1, GIP, and glucagon. These signaling pathways are involved in different processes that may be relevant for appetite, satiety, blood sugar regulation, energy balance, and body weight.

The exact clinical benefit and long-term safety profile are still being investigated. Existing clinical trial data show that retatrutide can influence several metabolic signaling pathways. However, this should not be interpreted to mean that the active ingredient is safe or available for patients outside clinical trials.

• GLP-1: This signaling pathway is involved, among other things, in satiety, hunger, food intake, and blood sugar-related metabolic processes.
• GIP: GIP is another incretin hormone and plays a role in metabolic processes, insulin response, and energy utilization.
• Glucagon: Glucagon is involved, among other things, in the regulation of sugar and energy metabolism.
• Triple agonist: By combining these three signaling pathways, retatrutide differs from GLP-1 receptor agonists such as semaglutide or liraglutide and from dual-acting active ingredients such as tirzepatide.

The effect is not the same for every person. Dose, comorbidities, tolerability, nutrition, physical activity, study design, and treatment duration also influence how much body weight and metabolic markers may change.

Retatrutide and triple agonism

The term triple agonist describes the key difference between retatrutide and many already known active ingredients used in medical weight loss. While semaglutide and liraglutide are classified as GLP-1 receptor agonists and tirzepatide additionally targets the GIP signaling pathway, retatrutide is being investigated as an active ingredient with activity at GLP-1, GIP, and glucagon receptors.

This threefold receptor activity is one important reason why retatrutide is being closely watched scientifically. At the same time, it makes careful benefit-risk evaluation especially important. The more signaling pathways an active ingredient influences, the more relevant controlled clinical trial data, long-term observation, and regulatory review become.

Signaling pathway	Medical classification	Possible relevance for weight and metabolism
GLP-1	Incretin signaling pathway	Can influence hunger, satiety, food intake, and blood sugar-related processes
GIP	Incretin signaling pathway	Can influence metabolic processes and insulin response in connection with food intake
Glucagon	Hormonal metabolic signaling pathway	Is involved in sugar and energy metabolism and is being studied in the context of energy expenditure and metabolic regulation

Clinical evidence on retatrutide

Retatrutide has been and is being studied in clinical trials in people with obesity or significant excess weight. Study reports describe substantial changes in body weight, especially at higher doses and with longer treatment duration. These results are scientifically relevant, but they must always be interpreted in the context of study design, participant selection, dosing, side effects, and observation period.

A phase 2 study published in the New England Journal of Medicine described retatrutide as a triple-hormone receptor agonist for obesity. Current phase 3 data have also been publicly reported and show that retatrutide remains one of the most closely watched active ingredients in obesity research.

For patients, the key point is that clinical trial data are not the same as regular approval. Only a regulatory review determines whether a medication is approved for a specific use, which patient groups may be eligible, which risks must be considered, and under which conditions it may be used.

Current clinical trial and approval status of retatrutide

At this time, no regular approval of retatrutide as a weight loss medication has been documented for Germany or the European Union. Retatrutide is still in clinical development. This means that the active ingredient is being scientifically investigated, but it is not automatically available as a regular treatment.

This distinction is especially important for patients. Clinical trials, media reports, or search trends do not mean that an active ingredient is already approved, available in Germany, or medically suitable. The Body Clinic does not currently offer retatrutide and cannot currently prescribe it.

Which medication-based options are currently available and medically appropriate should be assessed individually by a physician. Our page about weight loss medications for medical weight management provides an overview of available treatment approaches.

Retatrutide as an injection in clinical trials

Retatrutide is being studied as an injection in clinical trials. A once-weekly administration is often described in this context. However, this should not be interpreted to mean that retatrutide is available as a finished medication in Germany or that it can be used independently.

Form	Classification	Status	Important to know
Injection	Retatrutide in clinical trials	Experimental active ingredient	No regular treatment at The Body Clinic; do not obtain it without medical assessment or outside approved use

Patients who would like to understand the difference between injectable and oral treatment options can also refer to the overview on weight loss with injections and medical supervision. Patients interested in oral options can find further information on weight loss tablets after medical assessment.

Who could retatrutide become medically relevant for?

Whether retatrutide may become medically relevant for certain patient groups in the future depends on the results of ongoing and future studies, regulatory evaluations, approval decisions, and safety data. For this reason, this page currently focuses on the medical classification of the active ingredient, not on a treatment recommendation.

A medical assessment for medication-based weight loss may generally be particularly relevant if one or more of the following criteria apply:

• Obesity or significant excess weight
• Weight-related comorbidities
• Previous unsuccessful weight loss attempts despite dietary changes and physical activity
• Increased health risk due to weight
• A desire for physician-supervised treatment instead of using medication independently
• Interest in medically assessed and currently available treatment options

At The Body Clinic, a specific active ingredient is not automatically recommended. Instead, physicians assess whether a currently available weight loss medication, another treatment concept, or a non-medication-based approach may be better suited to the patient’s starting point. Depending on the situation, weight loss without medication with an individual plan may also be more appropriate.

Safety aspects of experimental active ingredients

Special caution is important with experimental active ingredients such as retatrutide. As long as an active ingredient is not regularly approved and available, the regulatory evaluations, product information, and instructions for use required for broad clinical use are not yet available. This includes dosing, patient selection, contraindications, interactions, side effect management, and long-term safety.

Patients should therefore not buy or use retatrutide independently. Offers from unsafe online sources may carry significant risks. These include unclear origin, unverified quality, incorrect dosing, contamination, lack of cold-chain control, lack of medical supervision, and possible harm to health.

Offers from social media, forums, messaging groups, or unverifiable online shops are especially problematic. With experimental active ingredients, it cannot be reliably assessed whether the product actually contains the stated active ingredient, what concentration it contains, or whether it was manufactured safely.

Additional context on medical indications and off-label questions is provided in our article on indications and off-label use for weight loss medications.

Possible side effects of retatrutide

Like other incretin-based active ingredients, retatrutide can cause side effects. Because the active ingredient has not yet been regularly approved as a medication for broad use, complete benefit-risk evaluations and long-term safety data are especially important.

Gastrointestinal symptoms have been described in clinical trials. These may include nausea, vomiting, diarrhea, constipation, or abdominal pain. Other symptoms or adverse effects are also possible. Which risks would be relevant in an individual case would need to be assessed by a physician.

Special medical attention is important, among other things, in cases of:

• existing gastrointestinal conditions
• type 2 diabetes or other metabolic disorders
• cardiovascular disease or increased cardiovascular risk
• regular use of other medications
• previous intolerance to GLP-1 or GIP/GLP-1 medications
• unclear symptoms before starting treatment
• pregnancy, breastfeeding, or plans to become pregnant

Patients can find more information about the tolerability of established GLP-1 medications, for example, on our page about side effects of Wegovy with semaglutide.

Retatrutide, semaglutide, tirzepatide, and liraglutide compared

Retatrutide is often compared with semaglutide, tirzepatide, and liraglutide. This comparison is understandable, but it should be interpreted carefully. Semaglutide, tirzepatide, and liraglutide are active ingredients found in already approved medications. Retatrutide, by contrast, is still in clinical development and is not currently available at The Body Clinic.

Criterion	Retatrutide	Semaglutide	Tirzepatide	Liraglutide
Active ingredient class	GLP-1/GIP/glucagon receptor agonist	GLP-1 receptor agonist	GIP/GLP-1 receptor agonist	GLP-1 receptor agonist
Known medications	No regularly approved medication documented for Germany/EU	Wegovy, Ozempic, Rybelsus	Mounjaro	Saxenda
Administration	Studied as an injection in clinical trials	Injection or tablet, depending on the medication	Injection once weekly	Injection once daily
Key characteristic	Experimental triple agonist targeting GLP-1, GIP, and glucagon	GLP-1 active ingredient available in different dosage forms	Dual mechanism of action through GIP and GLP-1	GLP-1 active ingredient with daily administration
Availability at The Body Clinic	Not currently offered	To be assessed depending on the medication and medical suitability	To be assessed depending on the medication and medical suitability	To be assessed depending on the medication and medical suitability
To be assessed by a physician	Approval status, availability, clinical data, side effects, long-term safety, and individual suitability	Indication of the specific medication, current medication, risks, and treatment goal	BMI, comorbidities, tolerability, contraindications, and treatment goal	Suitability, daily administration, side effects, and long-term treatment strategy

Patients who would like a broader comparison of the active ingredient groups can find an overview on the hub page active ingredients in weight loss medications. The detailed pages on semaglutide as an active ingredient, tirzepatide as an active ingredient, and liraglutide as an active ingredient can also help explain the differences.

Retatrutide at The Body Clinic

The Body Clinic supports patients with medical weight loss through an individual treatment concept. The focus is not on quickly using a specific active ingredient, but on determining which treatment option is medically appropriate, tolerable, available, and suitable for long-term medical support.

Retatrutide is not currently offered by The Body Clinic. As part of the medical assessment, physicians therefore discuss which currently available medications or non-medication-based strategies may be better suited to the patient’s starting point. Previous weight loss attempts, pre-existing conditions, current medication, possible side effects, and personal treatment goals are also taken into account.

Why medical supervision matters in weight loss is also discussed in our article on medical weight loss programs for obesity.

Frequently asked questions about retatrutide as an active ingredient

What is retatrutide?

Retatrutide is an experimental active ingredient being investigated in obesity and metabolic research. It targets GLP-1, GIP, and glucagon receptors and is therefore described as a triple agonist.

What does triple agonist mean in relation to retatrutide?

Triple agonist means that retatrutide targets three receptor systems: GLP-1, GIP, and glucagon. This distinguishes the active ingredient from pure GLP-1 receptor agonists and dual GIP/GLP-1 active ingredients.

How does retatrutide work?

Retatrutide may influence processes related to hunger, satiety, blood sugar regulation, energy balance, and metabolism through GLP-1, GIP, and glucagon signaling pathways. The exact clinical benefit and long-term safety profile are still being investigated.

Is retatrutide a GLP-1 active ingredient?

Retatrutide acts, among other things, at the GLP-1 receptor. At the same time, it also targets GIP and glucagon receptors. For this reason, retatrutide is not classified as a pure GLP-1 active ingredient, but as a triple agonist.

Is retatrutide an approved medication?

At this time, no regularly approved medication containing retatrutide has been documented for Germany or the European Union. The active ingredient, medication, approval status, and availability should therefore be clearly distinguished.

Why is retatrutide compared with semaglutide and tirzepatide?

Retatrutide is compared with semaglutide and tirzepatide because all three active ingredients influence hormonal signaling pathways that are relevant for weight and metabolism. However, they differ significantly: semaglutide acts through GLP-1, tirzepatide through GIP and GLP-1, and retatrutide through GLP-1, GIP, and glucagon.

What side effects may occur with retatrutide?

Gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, or abdominal pain have been described in clinical trials. Other adverse effects are also possible. Because retatrutide has not yet been regularly approved for broad use, further safety data are especially important.

Can retatrutide be prescribed at The Body Clinic?

No. Retatrutide is not currently offered by The Body Clinic and cannot currently be prescribed there. Which currently available weight loss medications may be medically appropriate should be assessed individually by a physician.

Where can I find information about retatrutide as a potential medication?

Information about retatrutide as a potential medication, its availability, and current treatment status can be found on our page about retatrutide as a potential weight loss medication.

Sources

• Reuters: Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight, 2026.
• Jastreboff AM et al.: Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 2023.
• ClinicalTrials.gov: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight, TRIUMPH-1.
• Coskun T et al.: LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metabolism, 2022.